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BACKGROUND: The development of prostate cancer from a clinically localized, hormone-naive state to a hormone-
refractory phenotype involves a complex interplay of protein kinase C (PKC) and activator protein-1 (AP-1). Therefore, the
present study aimed to uncover the roles of PKC and AP-1 through midostaurin-mediated regulation—a multi-target protein
kinase inhibitor.
METHODS: Androgen Receptor-negative, hormone-refractory prostate cancer cells (PC-3) were used as an in-vitro model
system. The effect of midostaurin on cell viability was assessed by an MTT assay. Expression studies on PKC-α, PKC-d,
different AP-1 transcription factors, and AP-1 regulating genes were analyzed by semiquantitative RT-PCR, and protein levels
of Bcl-2 were evaluated by western blotting.
RESULTS: Midostaurin decreased the viability of hormone-refractory PC-3 cells. Furthermore, midostaurin signiﬁcantly
induced the transcripts of apoptotic-mediated PKC-d, tumor suppressor p53, cell cycle inhibitor p21cip1/waf1, death receptor
TNF-α, pro-apoptotic Bax, and Caspase-8, and eventually inhibited the expression of pro-survival PKC-ε, pro-oncogene c-Jun,
c-Fos, Fra-1, positive growth regulator cyclin D1, and anti-apoptotic Bcl-2. In addition, midostaurin also decreased the protein
expression of anti-apoptotic Bcl-2.
CONCLUSION: The present study provided evidence that midostaurin suppresses tumor growth and induces apoptosis in
hormone-refractory PC-3 cells via modulation of PKC-d and PKC-ε expression, and regulation of PMA-altered c-Jun, c-Fos,
and Fra-1 AP-1 transcription factors and their target genes involved in cell cycle regulation (cyclin D1, p53, p21, Bcl-2, and
TNF-α). Thus, pharmacological targeting of PKC and AP-1 factors may have therapeutic potential against hormone-refractory
prostate cancer.
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Introduction
Protein kinase C (PKC) is a family of serine/threonine kinases
involved in the regulation of various cell functions including
proliferation, gene expression, differentiation, cytoskeletal
organization, cell migration, and apoptosis (Carter and Kane,
2004). PKCs have been linked to carcinogenesis because of
PKC activators, such as phorbol 12-myristate 13-acetate
(PMA), acting as tumor promoters (Blumberget al.,1984).
Furthermore, studies have suggested that PKC affects the
phenotype of high grade cancers, including skin, colon,
ovarian, brain, lung, breast, and prostate cancers, supporting
the role of PKC in early carcinogenesis and cancer
progression (Teicher 2006). PKCs are classiﬁed into conven-
tional (cPKC), novel (nPKC), and atypical PKCs based on
their structural and activation characteristics (Schenk and
Snaar-Jagalska, 1999). PKCs are capable of promoting
opposing responses, such as survival and growth arrest.
This paradigm of functional diversity is exempliﬁed by
nPKCs, such as PKC-ε that acts as a mitogenic or anti-
apoptotic kinase, and PKC-d, whose activation inhibits
proliferation or triggers an apoptotic response (Brodie and
Blumberg, 2003, Nakagawa et al.,2005). In particular, PKC-ε
is implicated in prostate tumor progression and the transition
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to androgen-independence (Koren et al., 2004; Aziz et al.,
2007). These ﬁndings led to PKC being considered as a
potential therapeutic target for hormone-refractory prostate
cancer.
The PKC signaling pathway exerts proliferative or anti-
proliferative effects through the downstream transcription
factor, activating protein 1 (AP-1). AP-1 plays a critical role
in the regulation of prostate cell proliferation, as well as
cancer progression (Angel et al., 1987, Ouyang et al., 2008)
and is known to determine the fate of cells, life or death, in
response to variety of extracellular stimuli. AP-1 mediates
responsiveness to phorbol ester tumor promoters, and is
composed of the cellular homologs of Jun and Fos
oncoproteins, implying its involvement in growth control
and oncogenesis (Wu et al., 2002). The broad combinatorial
possibilities provided by the large number of Jun/Jun or Jun/
Fos proteins determine their binding speciﬁcity and afﬁnity,
and consequently, the spectrum of regulated genes (Hess et
al., 2004). AP-1 has been implicated as a positive regulator of
cell proliferation through their ability to mediate expression
and function of cell cycle regulators, such as cyclin D1, p53,
and p21cip1/waf1, and can therefore stimulate G1-to-S-phase
transition and cell cycle progression. On the other hand, AP-1
may increase cell survival by regulating genes such as anti-
apoptotic Bcl-2 and death receptor TNF-α (Shaulian and
Karin, 2001). Despite several studies, the mechanism behind
inhibiting PMA-induced AP-1 factors in hormone-refractory
prostate cancer is unclear.
Midostaurin, also known as PKC412, is a protein kinase
inhibitor originally developed for use against PKC, a serine/
threonine protein kinase family (Propper et al., 2001). It was
later shown that this compound is a multi-target protein
kinase inhibitor with a broad inhibition spectrum, (Fabbro et
al., 2000). It has been suggested that midostaurin exhibits its
anti-cancer effects through cell cycle arrest and increased
apoptosis (Bahlis et al., 2005, Fischer et al., 2010, Kawai et
al., 2015). However, not much is known about the exact
mechanisms of midostaurin regulation of nPKC isozymes,
expression of AP-1 factors, and AP-1 target genes involved in
hormone-refractory prostate cancer. Therefore, the present
study aimed to demonstrate the anti-proliferative effect of
midostaurin on nPKC isozymes, AP-1, and AP-1 target genes
using hormone-refractory prostate cancer cells (PC-3) as a
model system under in vitro conditions.
Materials and methods
Materials
Human prostate cancer cells (PC-3) were purchased from
NCCS (Pune, India). Phorbol 12-myristate 13-acetate (PMA),
midostaurin (PKC412), TRIzol, and forward and reverse
primers for PKC-α, PKC-d, different AP-1 transcription
factors, and AP-1 regulating genes (Table 1) were purchased
from Sigma-Aldrich (St Louis, USA). Superscript reverse
transcriptase for RT-PCR was purchased from Invitrogen
(California, USA). Roswell Park Memorial Institute-1640
(RPMI-1640) medium, fetal bovine serum (FBS), penicillin,
streptomycin, glutamine, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), dimethyl sulfoxide
(DMSO), and trypan blue dye and 6 and 96-wellplates were
purchased from Himedia (Mumbai, India). Primary anti-
bodies against GAPDH and Bcl-2 were purchased from
NeoBiolab (Massachusetts, USA), and goat anti-rabbit HRP-
conjugated secondary antibody was purchased from Imgenex
India Pvt. Ltd. (Bhubaneswar, India). Taq DNA polymerase
(1 U/µL) and Luminata Forte Western HRP substrate were
procured from Merck-Millipore (Mumbai, India).
Culturing of PC-3 Cells and treatment
PC-3 cells were grown in 25-cm2 culture ﬂasks in RPMI-1640
media supplemented with 10% FBS, 100 U/mL penicillin,
100 mg/mL streptomycin, and 2 mM L-glutamine. Cells were
cultured at 37°C in a humidiﬁed atmosphere of 5% CO2.
Flasks containing 90%–100% conﬂuent cells were sub-
cultured in 96-well plates (3  103 cells/well) and 6-well
plates (5  105 cells/well) for treatment with modulators.
MTT assay
PC-3 cells (3  103 cells/well) in 200 µL of medium were
seeded in 96-well microtiter plates and incubated overnight
at 37°C with a supply of 5% CO2. Cells were treated with
media containing various concentrations of PMA or mid-
ostaurin for 48 h, washed with PBS, treated with 20 µL of
MTT (5 mg/mL), and then incubated further for 4 h at 37°C in
a CO2 incubator. Live cells take up the yellow MTT
compound and mitochondrial enzymes reduce it to insoluble
blue formazan products, that are then dissolved in DMSO
(100 µL) and visualized. Absorbance was measured at 540
nm using a multimode plate reader (Massachusetts, USA).
The effect of PMA and midostaurin on cell viability was
calculated and represented as the percentage of viable cells
compared with control.
RNA isolation and semiquantitative RT-PCR analysis
Overnight cultured PC-3 cells (5  105 cells/well) in 6-well
plates were treated with or without PMA (10 nM),
midostaurin (10 µM), or PMA (10 nM) + midostaurin (10
µM) for 48 h. Total RNAwas isolated from the samples using
TRIzol reagent as per manufacturer’s instructions. Reverse
transcription of RNA and PCR analysis was carried out
according to a previously described protocol (Hegde et al.,
2016). In brief, total RNA (2 µg) was reverse transcribed
using oligo dT primers and superscript reverse transcriptase.
The cDNAwas subjected to 30 cycles of PCR using different
forward and reverse primer pairs for PKC-d, PKC-ε, several
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AP-1 factors, and AP-1 regulating genes (Babu et al., 2013)
using appropriate annealing temperatures (Table 1) in a
gradient Eppendorf thermocycler. Ampliﬁed PCR products
were analyzed on 1% agarose gels using 1  TAE buffer.
Relative mRNA levels were quantiﬁed using an image
analysis software (ImageJ). Expression of β-actin mRNAwas
used as a positive control and for normalization.
Western blot analysis
PC-3 cells (5105 cells/well) in 6-well plates were treated
with or without PMA (10nM), or PMA (10nM)+midostaurin
(10 μM) for 48 h and were subjected to western blot analysis
as described previously (Patil et al., 2016) with minor
modiﬁcations. Cells were lysed in 0.2 mL cold lysis buffer
[50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, and
100 µM PMSF], and protein concentrations of cell lysates
were estimated by Bradford’s method (Bradford 1976). Equal
amounts of protein (40 mg/lane) were electrophoresed on 12%
resolving sodium dodecyl sulfate–polyacrylamide gels and
transferred onto PVDF membranes. Membranes were
blocked with 5% fat-free milk (Carnation) for 1 h at
room temperature. Blots were incubated with primary
antibody (anti-Bcl-2) in blocking solution (1:500) for 1 h,
washed, and then incubated with anti-rabbit HRP-linked
secondary antibody (1:1000) and further incubated for 1 h at
room temperature. Proteins were visualized with Luminata
Forte Western HRP substrate (according to manufacturer’s
Table 1 Sequence of primers used in RT-PCR studies




61 97 Present study
PKC-ε F:CTTCTCGACCCCTACATTGCC
R:GCAGGTGCAGACTTGACACTG




64 525 Babu et al., 2013
Jun-D F: CGCAGCCTCAAACCCTGCCTTTCC
R: AAACAGGAATGTGGACTCGTAG
64 500 Babu et al., 2013
Jun- B F: CCAGTCCTTCCACCTCGACGTTTACAAG
R: GACTAAGTGCGTGTTTCTTTTCCACAGTAC
58 257 Babu et al., 2013
c-Fos F: TCTTCCTTCGTCTTCACC
R: AATCAGAACACACTATTGCC
58 577 Babu et al., 2013
Fra-1 F: AGGAAGGAACTGACCGAC
R: GAAGGGGAGGAGACATTG
60 497 Babu et al., 2013
Fra-2 F: AGGAGGAGAGATGAGCAG
R: GGATAGGTGAAGACGAGG
60 518 Babu et al., 2013
Fos-B F: TGTCCCAGGGAAATGTTTCAGGC
R: ACTGGTAGTTCCGCTGGTGGAAGG
56 451 Present study
Cell cycle regulators and apoptotic genes
P53 F: GAGCCCCCTCTGAGTCAG
R: GCAAAAACATCTTGTTGAG
56 375 Babu et al., 2013
P21 F:GATCACAAGCAGTGGGGTGA
R:CTGAGTGACTGCACGACCTT
58 160 Present study
Cyclin D1 F: AGACCTGCGCGCCCTCGGTG
R: GTAGTAGGACAGGAAGTTGTTG
58 574 Babu et al., 2013
TNF-α F: CAAGCCTGTAGCCCATGTTGTAGC
R: ATCCCAAAGTAGACCTGCCCAGAC
58 430 Pail et al., 2013
Bax F: AAGCTGAGCGAGTGTCTCAAGCGC
R: TCCCGCCACAAAGATGGTCACG
61 366 Babu et al., 2013
Bcl-2 F: AGATGTCCAGCCAGCTGCACCTGAC
R: AGATAGGCACCCAGGGTGATGCAAGCT
62 365 Babu et al., 2013
Caspase-8 F: GATATTGGGGAACAACTGGAC
R: CATGTCATCATCCAGTTTGCA
58 366 Present Study
β-actin F: TACCACTGGCATCGTGATGGACT
R: TCCTTCTGCATCCTGTCGGCAAT
62 516 Babu et al., 2013
Columns 3 and 4 show annealing temperatures and the size of the ampliﬁed products. F, forward, R, reverse.
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instructions) using a Syngene gel documentation system
(Maryland, USA). GAPDH was used as an internal control
for normalization. Immunoreactive bands were quantiﬁed
using the image analysis software, ImageJ.
Statistical analysis
All values are expressed as the mean±standard deviation.
Each value represents the mean of at least 3 independent
experiments in each group. MTT assays, images of
semiquantitative RT-PCR gels, and western blotting data
were analyzed by one-way ANOVA followed by post-hoc
Tukey test. Values were considered statistically signiﬁcant if
*p< 0.05 and **p< 0.005 compared with control, and if
#p< 0.05 compared with PMA-treated samples.
Results
Anti-proliferative effect of midostaurin on hormone-
refractory PC-3 cells
To examine the effect of midostaurin on cell viability, PC-3
cells were treated with or without different concentrations of
midostaurin (1 nM–10 mM) for 48 h, and then cell viability was
determined by MTT assays. PC-3 cells treated with mid-
ostaurin at concentrations of 1 nM and 10 nM had no effect on
cell viability, while signiﬁcant decreases in cell viability was
observed from 50 nM and higher. A maximum of 40%
decrease in cell viability was observed at 10 mMofmidostaurin
(Fig. 1). Similar results were obtained after counting the
number of viable cells by the trypan blue exclusion method
using a Neubauer counting chamber (data not shown).
Midostaurin induces apoptotic PKC-d and inhibits
pro-survival PKC-ε mRNA expression in PC-3 cells
PC-3 cells were treated with PMA (10 nM), midostaurin
(10 µM), or PMA (10 nM) in combination with midostaurin
(10 µM) for 48 h, and the expression levels of nPKC
isozymes (PKC-d and PKC-ε mRNA), were analyzed by
semiquantitative RT-PCR. Results showed that PMA exerts
almost had no effect on PKC-d expression, but induced
PKC-ε mRNA expression by more than 38% compared with
control (Fig. 2). On the other hand, cells treated with
midostaurin or midostaurin in combination with PMA
showed signiﬁcant increases in the expression levels of
PKC-dmRNA by 52% and 46%, respectively, compared with
control. Furthermore, midostaurin or midostaurin and PMA
signiﬁcantly decreased mRNA levels of PKC-ε by 30% and
25%, respectively, compared with control, and by 50% and
45%, respectively, compared with PMA-treated samples.
Midostaurin inhibits the PMA-induced expression of
c-Jun, c-Fos, and Fra-1 mRNA in PC-3 cells
To analyze the effect of midostaurin on the mRNA expression
of different AP-1 factors, PC-3 cells were treated with PMA
(10 nM), midostaurin (10 µM), or PMA (10 nM) in
combination with midostaurin (10 µM) for 48 h, and the
expression patterns of AP-1 factors were measured by semi-
quantitative RT-PCR to analyze relative mRNA levels. The
results showed that cells treated with PMA signiﬁcantly
induced mRNA expression of c-Jun by 0.9-fold, c-Fos by
more than 2.4-fold, and Fra-1 by 1.8-fold, while the
expression of JunB decreased by 30% compared with the
control (Fig. 3). Treating cells with midostaurin or mid-
ostaurin combined with PMA signiﬁcantly decreased the
PMA-induced expression levels of c-Jun, c-Fos, and Fra-1,Figure 1 Effect of midostaurin on the viability of PC-3 cells.
Figure 2 Effect of PMA or midostaurin or PMA with midostaurin on the mRNAs of novel PKC isozymes in PC-3 cells.
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implying that c-Jun, c-Fos, Fra-1, and JunB may be involved
in the development of hormone-refractory prostate cancer.
Midostaurin modulates AP-1-regulated cell cycle
regulators and apoptotic genes
To analyze the effect of midostaurin on mRNA levels of AP-
1-regulated cell cycle regulators and apoptotic genes, PC-3
cells were treated with PMA (10 nM), midostaurin (10 µM),
or PMA (10 nM) in combination with midostaurin (10 µM)
for 48 h. The expression patterns of p53, p21, cyclin D1,
TNFα, Bax, Bcl-2, and caspase-8 were then measured by
semi-qRT-PCR for relative mRNA level analysis. The results
showed that cells treated with PMA signiﬁcantly induced the
growth regulator cyclin D1 and anti-apoptotic Bcl-2 by 30%
and 34%, respectively, compared with control, while
transcript levels of p53, p21, Bax, and caspase-8 were
unaffected (Fig. 4). However, midostaurin treatment, either
alone or in combination with PMA, resulted in an increase in
mRNA levels of tumor suppressors p53 and p21 by 1.8- and
1.5-fold, respectively, and induced expression of death
receptor TNF-α, pro-apoptotic Bax, and caspase-8 by 2-,
1.1-, and 1.3-fold increases, respectively. Midostaurin treat-
ment also decreased PMA-induced expression of cyclin D1
and Bcl-2 by 60% and 55%, respectively. Therefore, the
results conﬁrm the apoptotic effect of midostaurin on
hormone-refractory PC-3 cells.
Midostaurin inhibits PMA-induced expression of AP-1-
regulated, anti-apoptotic Bcl-2 protein
The present study also showed that PMA (10nM) signiﬁ-
cantly induced the protein expression of anti-apoptotic Bcl-2
by 0.8-fold compared with control. On the other hand,
treatment of cells with midostaurin (10μM) or midostaurin
combined with PMA signiﬁcantly decreased the expression
Figure 3 Effect of midostaurin on the PMA-induced expression of mRNAs of AP-1 factors in PC-3 cells.
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of anti-apoptotic Bcl-2 by 40% and 50%, respectively,
compared with control, and by 55% and 65%, respectively,
compared with PMA-induced expression (Fig. 5). These
results suggest that midostaurin inhibits cell proliferation and
promotes apoptosis in hormone-refractory PC-3 cells.
Discussion
In the present study, we revealed that midostaurin signiﬁ-
cantly suppresses proliferation of hormone-refractory PC-3
cells. Hormone-refractory, invasive prostate cancer is an end-
stage cancer that accounts for the majority of prostate cancer
patient deaths (Edwards and Bartlett, 2005). Knowledge
about the molecular mechanisms and regulatory molecules
involved in the transition from androgen-dependent to
androgen-independent prostate cancer is essential for plan-
ning strategies to prevent and treat prostate cancer. Aberrantly
activated protein kinase C (PKC) and AP-1 transcription
Figure 4 Effect of midostaurin on mRNAs of AP-1 regulated cell cycle regulators and apoptotic genes in PC-3 cells.
Figure 5 Effect of midostaurin on PMA-induced expression of anti-apoptotic Bcl-2 protein levels in PC-3 cells.
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factors are regarded as potential therapeutic targets for
hormone-refractory prostate cancer (da Rocha et al., 2002,
Ouyang et al., 2008).
Midostaurin, a semi-synthetic alkaloid derived from
bacterial staurosporine, is a multi-target protein kinase
inhibitor that inhibits growth or induces apoptosis in several
types of cancer, blocks angiogenesis, and sensitizes cancer
cells to ionizing radiation—justifying its use in cancer
treatment (El Fitori et al., 2007). Midostaurin has the
advantage of oral administration and a longer half-life
because of the altered gastrointestinal absorption and plasma
protein binding (particularly to AAG) in cancer patients
(Propper et al., 2001). Therefore, to understand the anti-
proliferative mechanism of midostaurin, human prostate
adenocarcinoma cells cultured under in vitro conditions
were used as the model system in our study. Midostaurin
decreased the viability of PC-3 cells as measured by MTT
assays, suggesting that it exhibits cytotoxic effects on
androgen-independent prostate cancer cells. Our results are
in agreement with an earlier study reported by Kawai et al.
(2015), where midostaurin was found to preferentially
suppress proliferation of triple-negative breast cancer cells.
PKC is a family of serine/threonine kinases that are
important constituents of signaling pathways that control
mitogenesis, differentiation, survival, adhesion, motility, and
apoptosis, among others. At present, the PKC family consists
of 13 isoforms, and the distribution of different PKC isoforms
shows considerable tissue- and cell-speciﬁcity (Griner and
Kazanietz, 2007). PKC isozymes are commonly dysregulated
in cancer, and among the different isoforms, phorbol ester-
responsive novel isozymes PKC-d and PKC-ε are key
mediators involved in the regulation of prostate tumorigenesis
(Aziz et al., 2007). Our study demonstrated that PC-3 cells
exhibited mere expression of apoptotic-mediated PKC-d and
elevated expression of pro-survival PKC-ε. Previous studies
established that PKC-d arrests the G1-to-S phase transition of
the cell cycle by controlling the phosphorylation status of
retinoblastomas, and is implicated as a negative growth
regulator (Xiao et al., 2009). Emerging evidence suggests that
PKC-ε is a transforming oncogene, as PKC-ε was found to
contribute to tumorigenesis in prostate cancer through its
stimulatory effects on proliferation, anchorage-independent
growth, transition to androgen independence, and invasive-
ness, as well as its inhibitory effects on cell death (Basu and
Sivaprasad, 2007, Meshki et al., 2010). Our results showed
that midostaurin signiﬁcantly induced mRNA expression of
the apoptotic-mediated PKC-d isoform, and eventually
inhibited expression of the pro-survival PKC-ε isoform,
conﬁrming the anti-proliferative roles of midostaurin.
PKCs transmit signals to the nucleus via one or more
mitogen-activated protein kinase (MAPK) cascades, which
include Raf-1, MEKs, and ERKs (da Rocha et al., 2002).
Activated ERKs can activate Fos and Jun (AP-1 transcription
factors) enabling the expression of target genes that encode
enzymes required for key metabolic functions, such as cell
proliferation and invasion (Seger and Krebs, 1995). However,
expression patterns of AP-1 factors during PMA-induced
proliferation in hormone-refractory prostate cancer cells and
the role of midostaurin in the suppression of AP-1 factors
have not been addressed. Our previous study reported the
expression of the complete set of AP-1 factors (c-Jun, JunB,
JunD, c-Fos, Fra-1, Fra-2, and Fos-B) in both LNCaP and PC-
3 prostate cancer cells (Kavya et al., 2017). In the present
study, the effect of midostaurin on PMA-induced Jun/Fos
mRNA transcripts was demonstrated. Although all Jun and
Fos transcripts were expressed, only c-Jun, c-Fos, and Fra-1
expression was induced by PMA in PC-3 cells. Treatment of
PC-3 cells with midostaurin signiﬁcantly inhibited PMA-
stimulated c-Jun, c-Fos, and Fra-1 mRNA transcripts. The
results suggest that c-Jun, c-Fos, and Fra-1 AP-1 factors are
involved in proliferation and that midostaurin possesses anti-
proliferative activity in hormone-refractory prostate cancer
cells; therefore, further investigation is needed. AP-1
transcription factors regulate downstream genes, such as
p53, p21, cyclin D1, and Bcl-2, that are involved in the cell
cycle, suggesting important regulatory roles of AP-1 in cell
proliferation (Shaulian and Karin, 2001). Furthermore, our
study showed that midostaurin induced mRNA expression of
tumor suppressor p53 and p21cip1/waf1, death receptor TNF-α,
pro-apoptotic Bax, and caspase-8, and eventually inhibited
the expression of growth regulator cyclin D1 and anti-
apoptotic Bcl-2. Additionally, western blot analysis con-
ﬁrmed the decreased protein expression of Bcl-2 after
midostaurin treatment, indicating the anti-proliferative and
anti-cancerous effects of midostaurin on aggressive prostate
cancer cells, PC-3.
The present study provided evidence that midostaurin
suppresses tumor growth or induces apoptosis in PC-3 cells
via modulation of the novel PKC enzymes, PKCε (a pro-
survival kinase) and PKCd (an apoptotic kinase), as well as
regulation of PMA-altered AP-1 transcription factors (c-Jun,
c-Fos, Fra-1, and JunB), that in turn regulate secretion of AP-
1 targeted cell cycle regulators (cyclin D1, p53, p21, anti-
apoptotic Bcl-2, and death receptor TNF-α). Thus, pharma-
cological targeting of PKC and AP-1 transcription factors
may possess therapeutic potential for hormone-refractory
prostate cancer. Such approaches may further reﬁne our
understanding of the biology and biochemistry of castration-
resistant prostate cancer, enabling us to develop new
therapeutic opportunities against this disease.
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